MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 129088 | Name: FHND5071

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FHND5071 is a RET Inhibitor. FHND5071 demonstrated potent inhibitory activities against various RET kinases and related cell lines. The pharmacokinetic results showed that compound FHND5071 had a targeted distribution in lung, liver, and brain tissues, exhibited high central nervous system penetration, and enhanced pharmacokinetics and pharmacodynamics. Western blot analysis indicated that compound FHND5071 significantly inhibited the phosphorylation of RET and downstream molecules ERK and AKT in tumor tissues. Furthermore, compound FHND5071 markedly inhibited tumor growth, showing good in vivo efficacy and significant intracranial antitumor activity.

Chemical Structure

FHND5071
FHND5071
CAS#2761152-16-1

Theoretical Analysis

MedKoo Cat#: 129088

Name: FHND5071

CAS#: 2761152-16-1

Chemical Formula: C30H30D3N9O

Exact Mass: 538.2996

Molecular Weight: 538.67

Elemental Analysis: C, 66.89; H, 6.74; N, 23.40; O, 2.97

Price and Availability

Related CAS #
No Data
Synonym
FHND5071; FHND-5071; FHND 5071
IUPAC/Chemical Name
4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(4-(methyl-d3)piperazin-1-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
InChi Key
BLMSWRQOCWCQDM-FIBGUPNXSA-N
InChi Code
InChI=1S/C30H33N9O/c1-35-7-9-36(10-8-35)24-12-27(30-23(13-31)16-34-39(30)20-24)22-4-5-28(32-15-22)37-18-25-11-26(19-37)38(25)17-21-3-6-29(40-2)33-14-21/h3-6,12,14-16,20,25-26H,7-11,17-19H2,1-2H3/i1D3
SMILES Code
N#CC1=C2C(C3=CC=C(N4CC(C5)N(CC6=CC=C(OC)N=C6)C5C4)N=C3)=CC(N7CCN(C([2H])([2H])[2H])CC7)=CN2N=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 538.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

1: Han Y, Wen T, Wang J, Shi J, Zhu Y. Preclinical Pharmacokinetics and in vitro

Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor. Eur J Drug Metab

Pharmacokinet. 2023 Sep;48(5):595-614. doi: 10.1007/s13318-023-00844-6. Epub

2023 Aug 2. PMID: 37528327.

 

2: Wang X, Miao H, Ye X, Shi J, Jiang C, Long Z, Wen T, Lei M, Zhu Y. Design and

Discovery of Novel Selective RET Inhibitors with High Central Nervous System

Penetration, Enhanced Pharmacokinetics, and Pharmacodynamics. J Med Chem. 2025

Jun 25. doi: 10.1021/acs.jmedchem.5c01109. Epub ahead of print. PMID: 40556477.